CA2771190C - Heat shock protein binding compounds, compositions, and methods for making and using same - Google Patents

Heat shock protein binding compounds, compositions, and methods for making and using same Download PDF

Info

Publication number
CA2771190C
CA2771190C CA2771190A CA2771190A CA2771190C CA 2771190 C CA2771190 C CA 2771190C CA 2771190 A CA2771190 A CA 2771190A CA 2771190 A CA2771190 A CA 2771190A CA 2771190 C CA2771190 C CA 2771190C
Authority
CA
Canada
Prior art keywords
alkyl
pyrimidin
alkoxy
ylthio
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2771190A
Other languages
English (en)
French (fr)
Other versions
CA2771190A1 (en
Inventor
Gabriela Chiosis
Tony Taldone
Anna Rodina
Pallav Patel
Yanlong Kang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CA2771190A1 publication Critical patent/CA2771190A1/en
Application granted granted Critical
Publication of CA2771190C publication Critical patent/CA2771190C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
CA2771190A 2009-08-17 2010-08-17 Heat shock protein binding compounds, compositions, and methods for making and using same Expired - Fee Related CA2771190C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27210109P 2009-08-17 2009-08-17
US61/272,101 2009-08-17
PCT/US2010/045817 WO2011022440A2 (en) 2009-08-17 2010-08-17 Heat shock protein binding compounds, compositions, and methods for making and using same

Publications (2)

Publication Number Publication Date
CA2771190A1 CA2771190A1 (en) 2011-02-24
CA2771190C true CA2771190C (en) 2020-01-21

Family

ID=43607564

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2771190A Expired - Fee Related CA2771190C (en) 2009-08-17 2010-08-17 Heat shock protein binding compounds, compositions, and methods for making and using same

Country Status (13)

Country Link
US (3) US9567318B2 (https=)
EP (2) EP3205647B1 (https=)
JP (3) JP2013502424A (https=)
KR (1) KR101906146B1 (https=)
CN (2) CN108752280A (https=)
AU (1) AU2010284255B2 (https=)
BR (1) BR112012003637A2 (https=)
CA (1) CA2771190C (https=)
EA (1) EA201290062A1 (https=)
ES (2) ES2608670T3 (https=)
MX (1) MX353747B (https=)
NZ (3) NZ713361A (https=)
WO (1) WO2011022440A2 (https=)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
MX353308B (es) 2008-05-21 2018-01-08 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
NZ713361A (en) 2009-08-17 2017-06-30 Memorial Sloan Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
BR112013027448A2 (pt) * 2011-04-28 2020-09-01 Sloan-Kettering Institute For Cancer Research terapia de combinação com hsp90
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
EA201490230A1 (ru) 2011-07-08 2014-06-30 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч Применение меченых ингибиторов hsp90
US9696313B2 (en) * 2011-10-06 2017-07-04 Whitehead Institute For Biomedical Research HSF1 as a marker in tumor prognosis and treatment
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN105492429A (zh) 2013-07-02 2016-04-13 米伦纽姆医药公司 Sumo活化酶的杂芳基抑制剂
TW201605812A (zh) 2013-09-16 2016-02-16 拜耳製藥股份有限公司 經雙取代之三氟甲基嘧啶酮類及其用途
US9353078B2 (en) 2013-10-01 2016-05-31 New York University Amino, amido and heterocyclic compounds as modulators of rage activity and uses thereof
CA2934891C (en) 2014-01-16 2023-02-28 Nicholas Ryan DEPREZ Pyrimidinyloxy benzene derivatives as herbicides
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
WO2015107494A1 (en) * 2014-01-17 2015-07-23 Novartis Ag 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
ES2699351T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
JP6607870B2 (ja) * 2014-05-13 2019-11-20 メモリアル スローン ケタリング キャンサー センター Ｈｓｐ７０モジュレーターならびにその作製および使用方法
BR112016030787B1 (pt) 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso
CR20170077A (es) 2014-08-04 2017-06-26 Nuevolution As Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
MX387627B (es) 2014-09-17 2025-03-18 Memorial Sloan Kettering Cancer Center Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia
WO2016113205A1 (de) 2015-01-13 2016-07-21 Bayer Pharma Aktiengesellschaft Substituierte pentafluorethylpyrimidinone und ihre verwendung
WO2016149315A1 (en) 2015-03-18 2016-09-22 E. I. Du Pont De Nemours And Company Substituted pyrimidinyloxy pyridine derivatives as herbicides
WO2016176675A2 (en) 2015-04-30 2016-11-03 Nant Holdings Ip, Llc Patient treatment via teratogenic pharmaceutical compounds
TWI713530B (zh) 2015-06-05 2020-12-21 美商艾佛艾姆希公司 作為除草劑之嘧啶氧基苯衍生物
WO2016203405A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
US10485235B2 (en) 2015-07-13 2019-11-26 Fmc Corporation Aryloxypyrimidinyl ethers as herbicides
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
SG11201801856XA (en) 2015-09-18 2018-04-27 Kaken Pharmaceutical Co Ltd Biaryl derivative and medicine containing same
US20180280397A1 (en) 2015-10-05 2018-10-04 Memorial Sloan Kettering Cancer Center Rational combination therapy for the treatment of cancer
SG11201805286RA (en) * 2015-12-24 2018-07-30 Kyowa Hakko Kirin Co Ltd α,β-UNSATURATED AMIDE COMPOUND
KR102720461B1 (ko) 2016-01-22 2024-10-21 잔센파마슈티카엔.브이. Nik 억제제로서의 신규 6원 헤테로방향족 치환된 시아노인돌린 유도체
JP6910359B2 (ja) 2016-01-22 2021-07-28 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｉｋ阻害剤としての新たな置換されたシアノインドリン誘導体
WO2017160569A1 (en) * 2016-03-14 2017-09-21 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
MX388576B (es) 2016-06-07 2025-03-20 Jacobio Pharmaceuticals Co Ltd Derivados heterociclicos novedosos utiles como inhibidores de shp2.
WO2017216706A1 (en) 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
WO2018002219A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors
ES2805976T3 (es) 2016-06-30 2021-02-16 Janssen Pharmaceutica Nv Derivados heteroaromáticos en calidad de inhibidores de NIK
EP4302834A3 (en) * 2016-07-12 2024-07-17 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
WO2018118015A1 (en) 2016-12-19 2018-06-28 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
CA3048340A1 (en) 2017-01-10 2018-07-19 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
JP7240319B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての二環式化合物
KR20190110588A (ko) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘 화합물
AU2018218521C1 (en) 2017-02-07 2022-06-09 Oblique Therapeutics Ab Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
MA47450A (fr) 2017-02-07 2019-12-18 Oblique Therapeutics Ab Sulfinylpyridines et leur utilisation dans le traitement du cancer
JP2020507625A (ja) 2017-02-07 2020-03-12 オブリーク セラピューティクス アーベー ヘテロアリールスルホニル置換ピリジンおよび癌の治療におけるそれらの使用
CA3051539A1 (en) 2017-02-07 2018-08-16 Oblique Therapeutics Ab Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer
LT3483164T (lt) 2017-03-20 2020-05-11 Forma Therapeutics, Inc. Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai
EA202190196A1 (ru) 2017-03-23 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
CN110785413B (zh) 2017-05-02 2024-08-02 Fmc公司 作为除草剂的嘧啶氧基苯并稠合化合物
US11447471B2 (en) 2017-06-23 2022-09-20 Kyowa Kirin Co., Ltd. α,β-unsaturated amide compound
CA3074690A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
TW201930292A (zh) 2017-10-12 2019-08-01 美商銳新醫藥公司 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物
US11801284B2 (en) * 2017-12-13 2023-10-31 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating motor neuron diseases
JP7361693B2 (ja) 2017-12-15 2023-10-16 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての多環式化合物
WO2019177375A1 (ko) * 2018-03-13 2019-09-19 포로노이바이오 주식회사 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
RU2020133727A (ru) * 2018-03-21 2022-04-21 Сучжоу Пухе Биофарма Ко., Лтд. Ингибиторы shp2 и их применение
MX2020010719A (es) 2018-04-10 2020-11-06 Revolution Medicines Inc Composiciones de inhibidores de shp2, metodos para tratar el cancer y metodos para identificar a un sujeto con mutaciones en shp2.
FI3788040T3 (fi) 2018-04-30 2023-06-13 Ribon Therapeutics Inc Pyridatsinoneja parp7-inhibiittoreina
MX2020011565A (es) 2018-05-01 2021-01-29 Revolution Medicines Inc Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor.
IL312291A (en) 2018-05-01 2024-06-01 Revolution Medicines Inc C-26-linked rapamycin analogs as MTOR inhibitors
EP3853206B1 (en) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Treating sickle cell disease with a pyruvate kinase r activating compound
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
JP2022508651A (ja) 2018-10-08 2022-01-19 レヴォリューション・メディスンズ，インコーポレイテッド 癌を処置するためのｓｈｐ２阻害剤組成物および方法
MX2021010319A (es) 2019-03-01 2021-12-10 Revolution Medicines Inc Compuestos biciclicos de heteroarilo y usos de estos.
MX2021010323A (es) 2019-03-01 2021-12-10 Revolution Medicines Inc Compuestos bicíclicos de heterociclilo y usos de este.
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
PT3943491T (pt) 2019-03-19 2025-07-28 Voronoi Inc Derivado de heteroarilo, método para a produção do mesmo e composição farmacêutica que compreende o mesmo como componente eficaz
WO2020223229A1 (en) 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
MA55909A (fr) 2019-05-05 2022-03-16 Qilu Regor Therapeutics Inc Inhibiteurs de cdk
CN115141205A (zh) 2019-06-07 2022-10-04 锐新医药公司 Shp2抑制剂的固体形式
EP3994132A1 (en) 2019-07-03 2022-05-11 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
HRP20251148T1 (hr) 2019-09-19 2025-11-21 Novo Nordisk Health Care Ag Pripravci koji aktiviraju piruvat-kinazu r (pkr)
WO2021087025A1 (en) 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
TW202132316A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ｒａｓ抑制劑
IL322454A (en) 2019-11-04 2025-09-01 Revolution Medicines Inc ras inhibitors
AU2020377925A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
CN110702483B (zh) * 2019-11-07 2022-05-10 上海海洋大学 一种超快速鉴别海鲜或肉类的预处理方法
CA3156359A1 (en) 2019-11-08 2021-05-14 Adrian Liam Gill Bicyclic heteroaryl compounds and uses thereof
CN111646956B (zh) * 2019-11-14 2022-06-03 中山万远新药研发有限公司 一种哌嗪基取代的二苯基亚砜类化合物及其组合物和应用
EP4065231A1 (en) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
UY38994A (es) 2019-12-20 2021-07-30 Nuevolution As Compuestos activos frente a receptores nucleares
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
WO2021142026A1 (en) 2020-01-07 2021-07-15 Revolution Medicines, Inc. Shp2 inhibitor dosing and methods of treating cancer
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
AU2021245397A1 (en) 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors
TWI782504B (zh) 2020-05-08 2022-11-01 美商美國禮來大藥廠 (三氟甲基)嘧啶-2-胺化合物
TW202227425A (zh) * 2020-09-18 2022-07-16 南韓商沃若諾伊生物公司 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物
CN112487680B (zh) * 2020-11-27 2024-05-03 西安空间无线电技术研究所 一种用于评价和调控离子阱非谐性势的方法
JP7849366B2 (ja) 2020-12-22 2026-04-21 キル・レガー・セラピューティクス・インコーポレーテッド Ｓｏｓ１阻害剤およびその使用
AU2022235471A1 (en) * 2021-03-10 2023-09-21 Sumitomo Pharma Co., Ltd. Method for producing fusion protein
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CA3256390A1 (en) 2022-05-25 2023-11-30 Revolution Medicines, Inc. CANCER TREATMENT METHODS USING AN MTOR INHIBITOR
TW202542151A (zh) 2023-12-22 2025-11-01 美商銳格醫藥有限公司 Ｓｏｓ１抑制劑及其用途
CN118389553A (zh) * 2024-03-01 2024-07-26 中国科学技术大学 免疫增效rna分子及其组合物、疫苗与试剂盒

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB951432A (en) 1959-03-17 1964-03-04 Wellcome Found Pyrimidine derivatives and the manufacture thereof
US3248393A (en) * 1960-06-23 1966-04-26 Burroughs Wellcome Co 1, 3-diazaphenothiazines and method
GB990857A (en) 1961-10-13 1965-05-05 Wellcome Found 1,3-diazaphenothiazines
US4039543A (en) 1974-12-24 1977-08-02 Hoffmann-La Roche Inc. Benzylpyrimidines
CH605828A5 (https=) * 1974-12-24 1978-10-13 Hoffmann La Roche
US4096264A (en) 1975-12-09 1978-06-20 Merck & Co., Inc. Certain substituted imidazo [1,2-a] pyridines
DE3311703A1 (de) 1983-03-30 1984-10-04 Bayer Ag, 5090 Leverkusen Harnstoffderivate
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
BR9407799A (pt) * 1993-10-12 1997-05-06 Du Pont Merck Pharma Composição de matéria método de tratamento e composição farmaceutica
DE4423098A1 (de) * 1994-07-01 1996-01-04 Hoechst Ag Verwendung von Pyrimidingruppen enthaltenden konjugierten Verbindungen als Elektrolumineszenzmaterialien
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JPH09236070A (ja) 1996-02-29 1997-09-09 Denso Corp スタータ
US5707930A (en) * 1996-09-16 1998-01-13 Zeneca Limited 4-cycloalkyl-5-substituted pyrimidine compounds useful as crop protection agents
AU4198400A (en) 1999-04-06 2000-10-23 Krenitsky Pharmaceuticals Inc. Neurotrophic thio substituted pyrimidines
HK1054393B (en) * 2000-09-20 2009-08-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
AU2002227984B8 (en) 2000-12-18 2007-01-04 Actelion Pharmaceuticals Ltd. Novel sulfamides and their use as endothelin receptor antagonists
US6423720B1 (en) * 2001-02-01 2002-07-23 Duquesne University Of The Holy Ghost Pyrimidine compounds and methods for making and using the same
US7501429B2 (en) 2001-04-11 2009-03-10 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
ATE374753T1 (de) 2001-12-21 2007-10-15 Vernalis Cambridge Ltd 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung
HRP20050089B1 (hr) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
NZ540791A (en) 2003-02-13 2009-09-25 Banyu Pharma Co Ltd Novel 2-pyridinecarboxamide derivatives
NZ546044A (en) * 2003-08-29 2009-09-25 Vernalis Cambridge Ltd Pyrimidothiophene compounds
US20050070712A1 (en) * 2003-09-26 2005-03-31 Christi Kosogof Pyrimidine derivatives as ghrelin receptor modulators
CA2557372C (en) 2004-03-05 2013-01-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 antagonists
JP4906715B2 (ja) * 2004-05-08 2012-03-28 ニューロジェン・コーポレーション ４，５−ジ置換−２−アリールピリミジン類
JP2008533166A (ja) * 2005-03-16 2008-08-21 ターゲジェン インコーポレーティッド ピリミジン化合物および使用法
ES2562056T3 (es) 2005-09-01 2016-03-02 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores P2X3 y P2X2/3
WO2007131034A1 (en) 2006-05-03 2007-11-15 The Regents Of The University Of Michigan Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
JP2008081492A (ja) * 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
US20080124407A1 (en) 2006-10-10 2008-05-29 University Of Washington Inhibiting cyp3a4 induction
EA017405B9 (ru) 2006-12-08 2014-05-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
PT2114900T (pt) * 2007-01-31 2019-01-17 Ym Biosciences Australia Pty Compostos à base de tiopirimidina e as suas utilizações
TW200911240A (en) 2007-06-11 2009-03-16 Kyowa Hakko Kogyo Kk Anti-tumor agent
WO2009023846A2 (en) * 2007-08-15 2009-02-19 The Research Foundation Of State University Of New York Methods for heat shock protein dependent cancer treatment
WO2009061345A2 (en) 2007-11-07 2009-05-14 Cornell Research Foundation, Inc. Targeting cdk4 and cdk6 in cancer therapy
PE20091236A1 (es) * 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
JP2012529512A (ja) 2009-06-08 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー トリアジン誘導体類及びそれらの治療応用
NZ713361A (en) 2009-08-17 2017-06-30 Memorial Sloan Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
WO2014078294A1 (en) 2012-11-13 2014-05-22 Memorial Sloan-Kettering Cancer Center Indole compounds and their use as antimicrobials
JP6607870B2 (ja) 2014-05-13 2019-11-20 メモリアル スローン ケタリング キャンサー センター Ｈｓｐ７０モジュレーターならびにその作製および使用方法
WO2016203405A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
CA2998753A1 (en) 2015-09-18 2017-03-23 St. Jude Children's Research Hospital Methods and compositions of inhibiting dcn1-ubc12 interaction

Also Published As

Publication number Publication date
MX2012001993A (es) 2012-02-29
WO2011022440A2 (en) 2011-02-24
KR101906146B1 (ko) 2018-10-10
US20190038626A1 (en) 2019-02-07
US10758538B2 (en) 2020-09-01
JP6465774B2 (ja) 2019-02-06
WO2011022440A3 (en) 2011-08-11
EP2467142A4 (en) 2013-03-06
NZ713361A (en) 2017-06-30
NZ598262A (en) 2014-05-30
CN102753177A (zh) 2012-10-24
MX353747B (es) 2018-01-26
JP2015212306A (ja) 2015-11-26
JP2013502424A (ja) 2013-01-24
EP2467142A2 (en) 2012-06-27
US20120252818A1 (en) 2012-10-04
AU2010284255A1 (en) 2012-03-08
CA2771190A1 (en) 2011-02-24
EP3205647A2 (en) 2017-08-16
EP3205647B1 (en) 2020-05-13
US10052325B2 (en) 2018-08-21
CN108752280A (zh) 2018-11-06
EA201290062A1 (ru) 2013-09-30
ES2608670T3 (es) 2017-04-12
KR20120117954A (ko) 2012-10-24
EP3205647A3 (en) 2017-09-27
ES2817700T3 (es) 2021-04-07
NZ623069A (en) 2015-11-27
WO2011022440A9 (en) 2016-11-10
BR112012003637A2 (pt) 2017-04-25
EP2467142B1 (en) 2016-09-21
JP2018188476A (ja) 2018-11-29
US9567318B2 (en) 2017-02-14
US20170165265A1 (en) 2017-06-15
AU2010284255B2 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
CA2771190C (en) Heat shock protein binding compounds, compositions, and methods for making and using same
CA2959347C (en) Ulk1 inhibitors and methods using same
TWI552752B (zh) 雜芳基化合物及其用途
TWI221470B (en) Pyrimidine derivatives and pharmaceutical compositions containing the same
KR101446742B1 (ko) Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
TWI480269B (zh) ２－硫代嘧啶酮類
JP2018197233A (ja) 新規な４，６−二置換アミノピリミジン誘導体
CN103052627A (zh) 作为fak抑制剂的嘧啶衍生物
CA2960692A1 (en) 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors
US7879853B2 (en) 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors
US10239881B2 (en) RIPK2 inhibitors and method of treating cancer with same
HK1241360A1 (en) 2-(pyrimidin-5-yl)-thiopyrimidine derivatives as hsp70 and hsc70 modulators for the treatment of proliferative disorders
HK1241360B (en) 2-(pyrimidin-5-yl)-thiopyrimidine derivatives as hsp70 and hsc70 modulators for the treatment of proliferative disorders
HK1175393B (en) 2-(pyrimidin-5-yl)-thiopyrimidine derivatives as hsp70 and hsc70 modulators for the treatment of proliferative disorders

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150812

MKLA Lapsed

Effective date: 20220817